周四盘前交易中，渤健公司（Biogen，股票代码：BIIB）股价大幅下跌5.65%，引发市场关注。
消息面上，渤健公司下调了2025年的全年利润预期。公司表示，预计第四季度某些与收购相关的研发支出将导致每股利润下降1.25美元。渤健公司将2025年调整后每股利润预期从此前的15.50美元至16.00美元区间，下调至14.50美元至15.00美元之间。
尽管渤健公司第三季度业绩表现亮眼，每股收益达4.81美元，远超分析师平均预期的3.88美元，但下调全年利润预期的消息仍然对股价造成了显著影响。值得注意的是，公司多发性硬化症治疗产品销售好于预期，其备受关注的阿尔茨海默氏症治疗药物Leqembi的销售也在稳步增长。然而，这些积极因素似乎未能抵消投资者对未来盈利前景的担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.